Cost‐effectiveness guidelines for reimbursement of pharmaceuticals: Is economic evaluation ready for its enhanced status?
Open Access
- 1 July 1992
- journal article
- editorial
- Published by Wiley in Health Economics
- Vol. 1 (2) , 85-92
- https://doi.org/10.1002/hec.4730010202
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Cost‐effectiveness guidelines for reimbursement of pharmaceuticals: Is economic evaluation ready for its enhanced status?Health Economics, 1992
- Discounting and health benefitsHealth Economics, 1992
- Economic Evaluation of PharmaceuticalsPharmacoEconomics, 1992
- Current practice in obtaining the "Q" in QALYs: a cautionary note.BMJ, 1991
- Economic Analysis Alongside Clinical Trials: Revisiting the Methodological IssuesInternational Journal of Technology Assessment in Health Care, 1991
- Quality-adjusted Life Years, Utility Theory, and Healthy-years EquivalentsMedical Decision Making, 1989
- The use of QALYs in health care decision makingSocial Science & Medicine, 1989
- Meta-Analyses of Randomized Controlled TrialsNew England Journal of Medicine, 1987
- Small-Area Variations in the Use of Common Surgical Procedures: An International Comparison of New England, England, and NorwayNew England Journal of Medicine, 1982
- WELFARE ECONOMICS AND COST BENEFT ANALYSIS IN HEALTH CARE1Scottish Journal of Political Economy, 1981